# Mark's Patent Commercialization Strategy

**Document Version**: 1.0
**Last Updated**: November 7, 2025
**Owner**: Chief Innovation Officer
**Purpose**: Strategy to commercialize US20220160847 and generate revenue for foundation

---

## üìã Table of Contents

1. [Patent Overview](#patent-overview)
2. [Market Opportunity](#market-opportunity)
3. [Commercialization Pathways](#commercialization-pathways)
4. [Revenue Model](#revenue-model)
5. [Development Roadmap](#development-roadmap)
6. [Partnership Strategy](#partnership-strategy)
7. [Regulatory Pathway](#regulatory-pathway)
8. [Financial Projections](#financial-projections)
9. [Risk Mitigation](#risk-mitigation)

---

## Patent Overview

### Patent Details

**Patent Number**: US20220160847
**Title**: Methods and Compositions for Treating Inflammatory Conditions
**Filing Date**: November 18, 2020
**Publication Date**: May 26, 2022
**Status**: Patent Application (pending full approval)
**Inventor**: Mark Egly
**Owner**: Mark Egly / Mark Egly Foundation

---

### Patent Claims

**Core Innovation**: Repurposing Alpha-1 Antitrypsin (AAT) protein for conditions beyond AATD

**Key Claims**:

**1. Firefighter Protection**:

- Prophylactic administration of AAT before smoke exposure
- Reduces acute lung injury from smoke inhalation
- Protects against long-term respiratory damage
- Dosing: Pre-exposure and/or post-exposure

**2. Military Applications**:

- AAT for burn pit exposure (Iraq/Afghanistan veterans)
- Protection against toxic inhalation injuries
- Treatment of deployment-related respiratory conditions

**3. Asthma Treatment**:

- AAT as adjunct therapy for severe or refractory asthma
- Reduces airway inflammation
- Improves lung function and symptom control

**4. General Inflammatory Lung Conditions**:

- Acute respiratory distress syndrome (ARDS)
- COVID-19 and viral pneumonia
- Chronic inflammatory lung diseases

---

### Scientific Rationale

**Why AAT Works Beyond AATD**:

**Anti-Inflammatory Properties**:

- AAT inhibits neutrophil elastase (enzyme that damages tissue)
- Also inhibits other proteases (cathepsin G, proteinase-3)
- Modulates immune response (reduces inflammation)

**Broad Applicability**:

- Smoke inhalation ‚Üí neutrophil activation ‚Üí elastase release ‚Üí lung damage
- AAT blocks this cascade
- Same mechanism in asthma, ARDS, viral pneumonia

**Proven Safety**:

- AAT used for 30+ years in AATD patients
- Excellent safety profile
- Derived from human plasma (biocompatible)

**Existing Evidence**:

- Small studies show AAT reduces inflammation in non-AATD conditions
- Case reports of AAT benefit in COVID-19, ARDS
- Growing literature on AAT's immunomodulatory effects

---

### Patent Scope & Protection

**Geographic Coverage**:

- US patent application (primary)
- International (PCT) application planned

**Patent Expiration**: ~2042 (20 years from filing)

**Freedom to Operate**:

- Existing AAT products (Prolastin, Zemaira, etc.) cover AATD use
- Mark's patent covers NEW uses (firefighters, military, asthma)
- No infringement on existing patents

**Defensive Position**:

- Pharmaceutical companies can't commercialize these uses without license from Mark

---

## Market Opportunity

### Target Markets

**Market 1: Firefighters** üî•

**Market Size**:

- 1.1 million firefighters in US (370K career, 745K volunteer)
- High risk: 50% develop chronic respiratory symptoms
- Leading cause of on-duty firefighter deaths: Cardiac + respiratory

**Value Proposition**:

- Prophylactic AAT before fire exposure
- Reduce acute smoke inhalation injury
- Prevent long-term COPD/lung disease
- Extend career length

**Market Potential**:

- Career firefighters (regular prophylaxis): 370,000 √ó $5,000/year = **$1.85B/year**
- Volunteer firefighters (post-exposure only): 745,000 √ó $500/year = **$372M/year**
- **Total: ~$2.2B/year US market**

**Payers**: Fire departments, municipalities, workers' comp insurance

---

**Market 2: Military** üéñÔ∏è

**Market Size**:

- 1.4 million active duty military
- 800K deployed to Iraq/Afghanistan (burn pit exposure)
- 30% of deployed veterans have respiratory symptoms

**Value Proposition**:

- Pre-deployment prophylaxis
- Post-exposure treatment (burn pits, IEDs, chemical exposure)
- Reduce long-term disability claims

**Market Potential**:

- Active duty deployments: 50,000/year √ó $5,000 = **$250M/year**
- Veteran treatment: 240,000 (30% of 800K) √ó $10,000 = **$2.4B/year**
- **Total: ~$2.65B/year US market**

**Payers**: Department of Defense, VA

---

**Market 3: Severe Asthma**

**Market Size**:

- 25 million Americans with asthma
- 3.6 million with severe asthma (uncontrolled despite treatment)

**Value Proposition**:

- Add-on therapy for severe/refractory asthma
- Reduce exacerbations and hospitalizations
- Steroid-sparing effect

**Market Potential**:

- Severe asthma patients: 3.6M √ó $15,000/year = **$54B/year**
- Even 5% penetration = **$2.7B/year**

**Payers**: Health insurance (commercial, Medicare, Medicaid)

---

**Market 4: Other Inflammatory Conditions**

**Potential Applications**:

- COVID-19 / viral pneumonia: $500M-$1B/year
- ARDS: $200M/year
- Cystic fibrosis: $100M/year
- Rheumatoid arthritis, vasculitis: $500M/year

**Total Addressable Market (TAM): ~$60-70 billion/year**

---

### Competitive Landscape

**Existing AAT Manufacturers**:

- **Grifols** (Prolastin-C): Market leader, ~50% share
- **CSL Behring** (Zemaira): ~30% share
- **Takeda** (Aralast NP, Glassia): ~20% share

**Their Position**:

- Currently only market for AATD (~8,000 patients)
- $100K-$200K per patient = $800M-$1.6B/year total AATD market
- Repurposing = 40-50x larger market
- **They will want Mark's patent to access this market**

**Other Competitors**:

- Anti-inflammatory drugs (corticosteroids, biologics)
- Neutrophil elastase inhibitors (in development)
- But AAT has unique advantages: Proven safety, multi-target effects

---

## Commercialization Pathways

### Option 1: Licensing to Pharmaceutical Company (PREFERRED)

**How It Works**:

- Mark/Foundation licenses patent to Grifols, CSL Behring, or Takeda
- They conduct clinical trials and pursue FDA approval
- Foundation receives upfront payment + milestone payments + royalties

**Pros**:

- ‚úÖ No capital investment required
- ‚úÖ Leverage pharma's expertise, infrastructure, regulatory experience
- ‚úÖ Faster path to market
- ‚úÖ Guaranteed revenue stream
- ‚úÖ Focus foundation on mission (not drug development)

**Cons**:

- ‚ùå Less control over development timeline
- ‚ùå Lower revenue potential (vs. developing in-house)
- ‚ùå Dependent on licensee's priorities

**Revenue Potential**:

- Upfront: $5-20M
- Milestones: $50-100M (Phase 1/2/3, FDA approval, sales targets)
- Royalties: 5-15% of sales = **$300M-$1B+/year** at peak

**Timeline**:

- Licensing deal: Year 1-2
- Clinical trials: Year 3-7
- FDA approval: Year 7-10
- Peak sales: Year 10-15

---

### Option 2: Co-Development Partnership

**How It Works**:

- Foundation + pharmaceutical company share development costs and profits
- 50/50 or 60/40 split

**Pros**:

- ‚úÖ Higher revenue share (vs. licensing)
- ‚úÖ More control over development
- ‚úÖ Shared risk

**Cons**:

- ‚ùå Foundation must invest capital ($10-50M)
- ‚ùå Requires pharma expertise (hire staff)
- ‚ùå Higher risk

**Revenue Potential**:

- Foundation invests: $10-50M
- Foundation share of profits: 40-50% = **$1-3B/year** at peak

**Timeline**: Similar to Option 1 (7-15 years)

---

### Option 3: In-House Development (NOT RECOMMENDED)

**How It Works**:

- Foundation develops drug independently
- Raise venture capital or partner with CRO (Contract Research Organization)

**Pros**:

- ‚úÖ Maximum revenue potential (100% of profits)
- ‚úÖ Full control

**Cons**:

- ‚ùå Requires $100-500M in capital
- ‚ùå High risk (most drugs fail)
- ‚ùå Diverts foundation from core mission
- ‚ùå 10-15 year timeline

**Not Feasible**: Foundation should focus on mission, not become biotech company

---

### **Recommended Pathway: Option 1 (Licensing)**

**Why**:

- Low risk, no capital investment
- Leverages existing pharma infrastructure
- Faster to patients
- Predictable revenue stream
- Keeps foundation focused on mission (education, advocacy, patient support)

---

## Revenue Model

### Licensing Deal Structure

**Typical Pharma License Agreement**:

**1. Upfront Payment**: $5-20M

- Paid at signing
- Compensates for patent rights and early development work

**2. Milestone Payments**: $50-100M total

- Phase 1 completion: $5-10M
- Phase 2 completion: $10-20M
- Phase 3 completion: $20-30M
- FDA approval: $20-40M
- Sales milestones: $5-10M each (e.g., $100M sales, $500M sales, $1B sales)

**3. Royalties**: 5-15% of net sales

- Early years (post-approval): 10-15%
- Mature market: 5-10%
- Tiered structure (higher % for higher sales)

**4. Minimum Annual Royalties** (after approval):

- Guarantees revenue even if sales lower than expected
- Typical: $1-5M/year

---

### Revenue Projections (Conservative)

**Licensing to Grifols (Example)**:

**Years 1-3 (2026-2028): Patent Licensing & Phase 1**:

- Upfront payment: $10M (Year 1)
- Phase 1 milestone: $5M (Year 3)
- **Total: $15M**

**Years 4-7 (2029-2032): Phase 2 & 3**:

- Phase 2 milestone: $15M (Year 5)
- Phase 3 milestone: $25M (Year 7)
- **Total: $40M**

**Years 8-10 (2033-2035): FDA Approval & Launch**:

- FDA approval milestone: $30M (Year 8)
- Launch year royalties: $10M (Year 9, 5% of $200M sales)
- Growth year royalties: $30M (Year 10, 5% of $600M sales)
- **Total: $70M**

**Years 11-20 (2036-2045): Mature Market**:

- Royalties: $50-150M/year (5-10% of $1-2B sales)
- **Total: $500M-$1.5B**

**20-Year Total (Conservative): $625M-$1.6B**

---

### Revenue Allocation

**How Foundation Uses Patent Revenue**:

**80% to Programs** (mission fulfillment):

- Research grants: 50%
- Patient assistance: 20%
- Education & advocacy: 10%

**20% to Reserves/Endowment** (sustainability):

- Build endowment for long-term stability
- Fund operations when patent expires

**Example** (Year 10, $50M royalty income):

- Research: $20M (quadruple current research budget)
- Patient assistance: $8M (help 1,000+ patients)
- Education: $4M (scale CME, AATD Aware certification)
- Reserves: $10M (build endowment)

---

## Development Roadmap

### Phase 1: Patent Strengthening & Market Analysis (2026)

**Q1-Q2: Patent Strategy**:

- Complete US patent prosecution (respond to USPTO)
- File international (PCT) applications (Europe, Asia)
- Conduct freedom-to-operate analysis
- Prior art search (ensure no competing patents)

**Q3-Q4: Market Research**:

- Firefighter market: Survey fire departments, interview chiefs
- Military market: Engage DOD, VA stakeholders
- Asthma market: KOL interviews, payer research
- Competitive intelligence (what are pharma companies developing?)

**Deliverable**: Investment memorandum for potential licensees

---

### Phase 2: Partnership Outreach & Negotiation (2027)

**Q1: Target Identification**:

- Prioritize pharma partners (Grifols, CSL Behring, Takeda)
- Secondary targets (Baxalta, Kamada, others)

**Q2-Q3: Initial Meetings**:

- Present patent and market opportunity
- Gauge interest and fit
- NDA (non-disclosure agreement) signed

**Q4: Term Sheet Negotiation**:

- Upfront payment, milestones, royalties
- Development timeline and responsibilities
- Legal negotiations

**Deliverable**: Signed term sheet with preferred partner

---

### Phase 3: Licensing Agreement & Phase 1 Trial (2028-2030)

**2028 Q1: Final Agreement**:

- Execute licensing agreement
- Receive upfront payment ($5-20M)

**2028-2030: Phase 1 Trial** (Pharma-led):

- **Indication**: Firefighter smoke inhalation protection
- **Design**: Randomized, placebo-controlled
- **N**: 50-100 healthy firefighters
- **Endpoints**: Safety, pharmacokinetics, inflammatory markers
- **Duration**: 12-18 months

**Foundation Role**:

- Recruit firefighter participants (leverage foundation network)
- Provide scientific input
- Patient advocacy

**Deliverable**: Phase 1 results, Phase 1 milestone payment ($5-10M)

---

### Phase 4: Phase 2 Trials (2031-2033)

**Phase 2a: Firefighters** (2031-2032):

- **N**: 200 firefighters
- **Design**: Randomized, placebo-controlled
- **Intervention**: AAT before smoke exposure (training or actual fires)
- **Endpoints**: Lung function, inflammatory markers, symptom scores
- **Duration**: 12-18 months

**Phase 2b: Severe Asthma** (2032-2033):

- **N**: 150 severe asthma patients
- **Design**: Randomized, add-on to standard therapy
- **Endpoints**: Exacerbation rate, lung function, quality of life
- **Duration**: 12 months

**Deliverable**: Phase 2 milestone payment ($10-20M)

---

### Phase 5: Phase 3 Trials (2034-2036)

**Phase 3: Firefighters** (2034-2036):

- **N**: 500-1,000 firefighters (multi-site)
- **Design**: Randomized, placebo-controlled, double-blind
- **Endpoints**:
  - Primary: Reduction in respiratory symptoms/injuries
  - Secondary: Lung function decline, career longevity
- **Duration**: 2-3 years

**Potential Phase 3: Asthma** (2035-2037):

- If Phase 2b successful
- **N**: 600-1,000 severe asthma patients
- **Endpoints**: Exacerbation rate, steroid reduction

**Deliverable**: Phase 3 milestone payment ($20-30M)

---

### Phase 6: FDA Approval & Launch (2037-2038)

**2037: FDA Submission**:

- Biologics License Application (BLA)
- Priority review (if granted, 6 months vs. 10 months)

**2038: FDA Approval & Launch**:

- FDA approval milestone payment ($20-40M)
- Commercial launch (firefighter indication)
- Marketing and sales ramp-up

**Deliverable**: FDA-approved product, royalty revenue begins

---

### Phase 7: Market Expansion (2039-2045)

**Additional Indications**:

- Military (burn pit exposure)
- Severe asthma
- ARDS, COVID-19 (if data supports)

**Geographic Expansion**:

- Europe, Asia, other markets

**Generics/Biosimilars**:

- Patent expires ~2042
- Royalties decline but market grows (lower price = more access)

---

## Partnership Strategy

### Target Partners (Priority Ranking)

**1. Grifols (TOP CHOICE)**:

- **Pros**: Market leader, most AAT experience, strong financials, global reach
- **Cons**: May be risk-averse (prefer proven markets)
- **Engagement Strategy**: Emphasize firefighter market (strong ROI), leverage Mark's story

**2. CSL Behring**:

- **Pros**: #2 player, innovative, interest in rare diseases
- **Cons**: Smaller AAT business than Grifols
- **Engagement Strategy**: Position as opportunity to leapfrog Grifols

**3. Takeda**:

- **Pros**: Large pharma with rare disease focus, two AAT products
- **Cons**: AAT not core focus (smaller division)
- **Engagement Strategy**: Highlight market expansion opportunity

**4. Emerging Biotech (Kamada, Baxalta)**:

- **Pros**: Nimble, innovative, may offer better terms
- **Cons**: Less capital, slower development
- **Engagement Strategy**: Fallback if big pharma not interested

---

### Negotiation Strategy

**Foundation's Position**:

- ‚úÖ Strong patent (novel use cases)
- ‚úÖ Large market opportunity ($60B+ TAM)
- ‚úÖ Proven drug (AAT safety established)
- ‚úÖ Supportive patient community (foundation can help recruit trials)

**What Foundation Wants**:

- Upfront payment: $10-20M (fund research and programs)
- Aggressive development timeline (patients need this NOW)
- Generous royalties: 10-15% (higher than typical because foundation brings recruitment, advocacy)
- Co-promotion rights (foundation messaging in marketing)

**What Pharma Wants**:

- Exclusive license (one company gets all indications)
- Lower royalties (5-8% typical)
- Flexibility on timeline (pharma moves slowly)
- Minimal foundation involvement (they want control)

**Win-Win Deal**:

- Exclusive license for 5 years, then non-exclusive (incentivizes speed)
- Tiered royalties: 15% first $500M sales, 10% next $500M, 8% thereafter
- Foundation helps recruit trial participants (reduces pharma costs)
- Joint steering committee (foundation has voice but pharma has final say)

---

### Legal & IP Considerations

**Due Diligence** (Pharma will review):

- Patent validity (is it novel, non-obvious, enabled?)
- Freedom to operate (any blocking patents?)
- Inventor ownership (Mark owns patent, not employer)
- Data supporting claims (scientific literature, preliminary studies)

**Foundation Preparation**:

- Hire patent attorney (specialized in pharma/biotech)
- Conduct own freedom-to-operate analysis
- Gather supporting scientific literature
- Prepare inventor declaration (Mark's story + science)

**Key Contract Terms**:

- Scope: Which indications, territories, fields of use
- Exclusivity: Exclusive vs. non-exclusive
- Sublicensing: Can licensee sublicense to others?
- Diligence: What if pharma doesn't develop (reversion clause)
- Royalty stacking: If other patents needed, how are royalties split?

---

## Regulatory Pathway

### FDA Approval Process for New Indication

**AAT Already FDA-Approved** (for AATD):

- Advantage: Safety established, can expedite trials
- Disadvantage: Still need efficacy data for new indications

**Regulatory Strategy**: **505(b)(2) Application**

- Relies on existing safety data from AATD use
- Only need to prove efficacy in new indication
- Faster and cheaper than full BLA

---

### Clinical Trial Design

**Firefighter Indication**:

- **Primary Endpoint**: Reduction in acute respiratory injury (symptom scores, inflammatory markers)
- **Secondary Endpoints**: Long-term lung function, career longevity, healthcare utilization
- **Challenges**:
  - Smoke exposure unpredictable (hard to control)
  - Solution: Training fires (controlled exposure) or observational cohort

**Asthma Indication**:

- **Primary Endpoint**: Exacerbation rate (reduction in asthma attacks)
- **Secondary Endpoints**: Lung function (FEV1), quality of life, steroid reduction
- **Advantages**: Well-established endpoints, faster timeline

---

### Regulatory Designations (to Pursue)

**Orphan Drug Designation**:

- If indication affects <200,000 people in US
- Benefits: 7-year market exclusivity, tax credits, FDA fee waivers
- **Firefighters**: 1.1M total (too many for orphan)
- **Severe asthma**: 3.6M (too many)
- **Not eligible** (but could pursue for rare subsets)

**Fast Track Designation**:

- For drugs treating serious condition + filling unmet need
- Benefits: More frequent FDA meetings, rolling review
- **Likely eligible** (firefighter lung injury = serious + unmet need)

**Breakthrough Therapy Designation**:

- For drugs showing substantial improvement over existing therapy
- Benefits: Intensive FDA guidance, accelerated approval possible
- **Possible** (if Phase 2 data very strong)

---

## Financial Projections

### 20-Year Revenue Forecast (Conservative)

| Year          | Phase                | Revenue   | Cumulative |
| ------------- | -------------------- | --------- | ---------- |
| 2026-2027     | Patent strengthening | $0        | $0         |
| 2028          | Licensing (upfront)  | $10M      | $10M       |
| 2029-2030     | Phase 1              | $5M       | $15M       |
| 2031-2033     | Phase 2              | $15M      | $30M       |
| 2034-2036     | Phase 3              | $25M      | $55M       |
| 2037-2038     | FDA approval         | $30M      | $85M       |
| 2039          | Launch year          | $10M      | $95M       |
| 2040          | Growth year          | $30M      | $125M      |
| 2041-2045     | Mature market        | $250M     | $375M      |
| **2026-2045** | **Total**            | **$375M** | **$375M**  |

**This is CONSERVATIVE**. Upside scenario: $1-2B over 20 years.

---

### Impact on Foundation Budget

**Current Budget** (Year 1, 2026): $500K
**With Patent Revenue** (Year 10, 2036): $15M+

**Example Budget (Year 10, $50M patent revenue)**:

- Research grants: $20M (40%)
- Patient assistance: $10M (20%)
- Education & advocacy: $8M (16%)
- Operations: $2M (4%)
- Reserves/Endowment: $10M (20%)

**Transformation**: From small startup nonprofit ‚Üí major disease foundation (like Michael J. Fox Foundation)

---

## Risk Mitigation

### Risk 1: Patent Rejected or Invalidated

**Likelihood**: Low (patent attorney vetted, strong claims)

**Mitigation**:

- Hire experienced patent attorney
- File continuation applications (expand claims)
- International patents (backup if US fails)

**Impact If Occurs**: No licensing revenue, but foundation continues with other funding

---

### Risk 2: No Pharma Interest

**Likelihood**: Low (large market, proven drug, strong patent)

**Mitigation**:

- Engage multiple companies simultaneously
- Offer attractive terms (lower upfront, higher royalties)
- Generate preliminary data (small pilot study) to de-risk

**Fallback**: Co-development with smaller biotech or academic partner

---

### Risk 3: Clinical Trials Fail

**Likelihood**: Moderate (all drugs have risk of failure)

**Mitigation**:

- Strong preclinical data before trials
- Adaptive trial design (can adjust based on early results)
- Multiple indications (if firefighter fails, try asthma)

**Impact**: No FDA approval, limited revenue (milestones paid for completed phases, but no royalties)

---

### Risk 4: Competitor Develops Alternative

**Likelihood**: Moderate (neutrophil elastase inhibitors in development)

**Mitigation**:

- Move quickly (get to market first)
- AAT has advantages (proven safety, multi-target)
- Patent protection (competitors can't use AAT without license)

**Impact**: Reduced market share, lower royalties (but still significant revenue)

---

### Risk 5: Market Smaller Than Expected

**Likelihood**: Low-Moderate (conservative estimates above)

**Mitigation**:

- Market research before licensing
- Include minimum royalty clause in agreement
- Multiple indications (diversify risk)

**Impact**: Lower revenue, but still significant (even 10% of projected = $50M+)

---

## Summary: Why This Matters

**Mark's patent is a game-changer**:

- ‚úÖ Generates **$100M-$1B+** revenue for foundation over 20 years
- ‚úÖ Funds research, patient assistance, education at scale
- ‚úÖ Achieves financial sustainability (not dependent on donations)
- ‚úÖ Helps millions beyond AATD (firefighters, military, asthma patients)
- ‚úÖ Validates Mark's vision and expertise

**Strategic Priorities** (Years 1-3):

1. Strengthen patent (complete US, file international)
2. Conduct market research (firefighter, military, asthma)
3. Engage pharmaceutical partners (Grifols, CSL Behring, Takeda)
4. Negotiate licensing agreement ($10-20M upfront)
5. Support clinical trial recruitment

**This is how we fund our mission for decades.**

---

**Questions or Partnership Opportunities?**

**Mark Egly Foundation**
üìß Email: innovation@markeglyfoundation.org
üåê Website: MarkEglyFoundation.org/patent

---

**Approved by**: Board of Directors & Patent Advisory Committee
**Effective Date**: January 1, 2026
**Review Date**: Annually
**Version**: 1.0

---

_"One patent. Millions helped. Billions in impact."_

**‚Äî Mark Egly Foundation**
